Free Trial
NASDAQ:SNPX

Synaptogenix (SNPX) Stock Price, News & Analysis

Synaptogenix logo
$2.24 +0.03 (+1.13%)
Closing price 05/23/2025 03:42 PM Eastern
Extended Trading
$2.24 +0.01 (+0.22%)
As of 05/23/2025 05:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Synaptogenix Stock (NASDAQ:SNPX)

Key Stats

Today's Range
$2.19
$2.29
50-Day Range
$2.01
$2.76
52-Week Range
$1.84
$5.05
Volume
2,869 shs
Average Volume
22,129 shs
Market Capitalization
$3.11 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.00
Consensus Rating
Buy

Company Overview

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

Synaptogenix Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
36th Percentile Overall Score

SNPX MarketRank™: 

Synaptogenix scored higher than 36% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Synaptogenix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Synaptogenix has received no research coverage in the past 90 days.

  • Read more about Synaptogenix's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Synaptogenix is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Synaptogenix is -0.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Synaptogenix has a P/B Ratio of 0.09. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.36% of the float of Synaptogenix has been sold short.
  • Short Interest Ratio / Days to Cover

    Synaptogenix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Synaptogenix has recently increased by 250.00%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Synaptogenix does not currently pay a dividend.

  • Dividend Growth

    Synaptogenix does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.36% of the float of Synaptogenix has been sold short.
  • Short Interest Ratio / Days to Cover

    Synaptogenix has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Synaptogenix has recently increased by 250.00%, indicating that investor sentiment is decreasing significantly.
    • Insider Buying vs. Insider Selling

      In the past three months, Synaptogenix insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      Only 2.73% of the stock of Synaptogenix is held by insiders.

    • Percentage Held by Institutions

      Only 10.34% of the stock of Synaptogenix is held by institutions.

    • Read more about Synaptogenix's insider trading history.
    Receive SNPX Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Synaptogenix and its competitors with MarketBeat's FREE daily newsletter.

    SNPX Stock News Headlines

    Synaptogenix Inc Ordinary Shares
    $19 for a FULL YEAR of stock picks?!
    Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. Discover how a $100 investment could give you exposure to Musk's private AI project — via one overlooked stock.
    Synaptogenix Announces $5.0 Million Financing
    See More Headlines

    SNPX Stock Analysis - Frequently Asked Questions

    Synaptogenix's stock was trading at $3.47 at the beginning of 2025. Since then, SNPX shares have decreased by 35.6% and is now trading at $2.2350.
    View the best growth stocks for 2025 here
    .

    Synaptogenix, Inc. (NASDAQ:SNPX) released its earnings results on Thursday, May, 15th. The company reported $0.04 earnings per share (EPS) for the quarter.

    Synaptogenix's stock reverse split before market open on Friday, April 5th 2024. The 1-25 reverse split was announced on Friday, April 5th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Friday, April 5th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

    Shares of SNPX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Synaptogenix investors own include SoFi Technologies (SOFI), Fluence Energy (FLNC), The9 (NCTY), Riot Platforms (RIOT), PubMatic (PUBM), Clean Energy Fuels (CLNE) and FuelCell Energy (FCEL).

    Company Calendar

    Last Earnings
    5/15/2025
    Today
    5/24/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    Pharmaceutical preparations
    Sub-Industry
    Pharmaceutical Products
    Current Symbol
    NASDAQ:SNPX
    Fax
    N/A
    Employees
    4
    Year Founded
    N/A

    Price Target and Rating

    Average Stock Price Target
    $14.00
    High Stock Price Target
    $14.00
    Low Stock Price Target
    $14.00
    Potential Upside/Downside
    +526.4%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    $-6,040,000.00
    Pretax Margin
    N/A

    Debt

    Sales & Book Value

    Annual Sales
    N/A
    Price / Cash Flow
    N/A
    Book Value
    $25.27 per share
    Price / Book
    0.09

    Miscellaneous

    Free Float
    1,319,000
    Market Cap
    $3.11 million
    Optionable
    Not Optionable
    Beta
    1.06
    2025 Gold Forecast: A Perfect Storm for Demand Cover

    Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

    Get This Free Report

    This page (NASDAQ:SNPX) was last updated on 5/24/2025 by MarketBeat.com Staff
    From Our Partners